题名 | Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects. | 作者 | Waring JF1, Dumas EO2, Abel S1, Coakley E2, Cohen DE2, Davis JW1, Podsadecki T2, Dutta S1. | 杂志 | J Viral Hepat. 2016 Feb;23(2):96-104. doi: 10.1111/jvh.12470. Epub 2015 Oct 5. | 年|卷|期 | J Viral Hepat. 2016 Feb;23(2):96-104. doi: 10.1111/jvh.12470. Epub 2015 Oct 5. | 页码 | J Viral Hepat. 2016 Feb;23(2):96-104. doi: 10.1111/jvh.12470. Epub 2015 Oct 5. | 链接 | http://www.ncbi.nlm.nih.gov/pubmed/26436610 |
本帖最后由 lo7ve77 于 2016-6-12 20:45 编辑
|